Last quarter (Q4 2023), Janux Therapeutics Inc's total revenue was $2.46M, a decrease of -13.50% from the same quarter last year. In Q4, Janux Therapeutics Inc's net income was $-11.76M. See Janux Therapeutics Inc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 6.04M	$ 8.61M	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 6.04M	$ 8.61M	-	-	-
Operating Expense	$ 81.06M	$ 75.70M	$ 36.57M	$ 4.84M	$ 3.77M
Operating Income	$ -75.03M	$ -67.09M	$ -36.57M	$ -4.84M	$ -3.77M
Net Non Operating Interest Income Expense	$ 14.69M	$ 4.03M	$ 257.00K	$ -206.00K	$ -233.00K
Other Income Expense	$ -4.55M	$ -200.00K	$ -3.64M	$ -1.74M	-
Pretax Income	$ -58.29M	$ -63.06M	$ -32.67M	$ -6.78M	$ -4.00M
Tax Provision	$ -2.83M	$ -3.75M	$ -328.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -58.29M	$ -63.06M	$ -32.67M	$ -6.78M	$ -4.00M
Basic EPS	$ -1.34	$ -1.52	$ -1.39	$ -1.06	$ -0.62
Diluted EPS	$ -1.34	$ -1.52	$ -1.39	$ -1.06	$ -0.62
Basic Average Shares	$ 176.07M	$ 41.47M	$ 23.53M	$ 6.42M	$ 6.42M
Diluted Average Shares	$ 176.07M	$ 41.47M	$ 23.53M	$ 6.42M	$ 6.42M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 81.06M	$ 75.70M	$ 36.57M	$ 4.84M	$ 3.77M
Net Income From Continuing And Discontinued Operation	$ -58.29M	$ -63.06M	$ -32.67M	$ -6.78M	$ -4.00M
Normalized Income	$ -23.72M	-	-	$ -6.78M	$ -4.00M
Interest Expense	-	-	-	$ 206.00K	$ 233.00K
EBIT	$ -58.29M	$ -63.06M	$ -32.93M	$ -6.58M	$ -3.77M
EBITDA	$ -46.49M	$ -64.40M	$ -32.99M	$ -6.57M	$ -3.77M

Currency in USD

Janux Therapeutics Inc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing